JCR Pharmaceuticals Co Ltd
JCR Pharmaceuticals's GHG Emissions Data Preview
In 2022, JCR Pharmaceuticals completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy), and Scope 3 (indirect emissions across the value chain).
JCR Pharmaceuticals has also provided a category-level breakdown for 10 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Scope 1 | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Total Scope 2 | ||||
Market-Based | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Location-Based | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Unspecified Calculation Method | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 3 | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data.  | 0000000 |
This table provides a simplified preview of selected GHG emissions data points. To access the complete dataset with full disclosures, detailed breakdowns, and source traceability, create a free account to view purchase options.
Insights into JCR Pharmaceuticals's Operational Emissions
In 2022, the total operational greenhouse gas (GHG) emissions of JCR Pharmaceuticals amounted to 10,985 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).
Compared to 2021, the total operational greenhouse gas (GHG) emissions of JCR Pharmaceuticals increased by 49.09%, suggesting that the company faced challenges in reducing its emissions from its core operations.
JCR Pharmaceuticals's Scope 1 Emissions Over Time
- Total Scope 1
- Year-over-Year Change
What are JCR Pharmaceuticals's Scope 1 emissions?
In 2022, the total Scope 1 emissions of JCR Pharmaceuticals were 3,315 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
Compared to the previous year (2021), JCR Pharmaceuticals's Scope 1 emissions increased by 48.52%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.
What are JCR Pharmaceuticals's Scope 2 emissions?
In 2022, JCR Pharmaceuticals reported Scope 2 greenhouse gas (GHG) emissions of 5,266 tCOâ‚‚e using the market-based method, and 7,670 tCOâ‚‚e using the location-based method.
What methodology does JCR Pharmaceuticals use for Scope 2 reporting?
In 2022, JCR Pharmaceuticals reported its Scope 2 emissions using the market-based method and using the location-based method.
JCR Pharmaceuticals's Scope 2 Emissions Over Time
- Total Scope 2 Location-Based
- Total Scope 2 Market-Based
- Total Scope 2 (Unspecified Calculation Method)
Insights into JCR Pharmaceuticals's Value Chain Emissions
In 2022, JCR Pharmaceuticals reported 79,466 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.
The 2022 disclosure of JCR Pharmaceuticals includes a breakdown across 10 of the 15 Scope 3 categories defined by the GHG Protocol, up from 0 in 2021, reflecting improved emissions accounting practices and greater transparency across the company's value chain
JCR Pharmaceuticals's Scope 3 Emissions Over Time
- Total Scope 3
- Year-over-Year Change
What are JCR Pharmaceuticals's Scope 3 emissions?
In 2022, JCR Pharmaceuticals reported total Scope 3 emissions of 79,466 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
Approximately 100% of these emissions originated from upstream activities such as purchased goods and capital goods, while 0% came from downstream activities like product use, distribution, and end-of-life treatment.
Compared to the previous year (2021), JCR Pharmaceuticals's Scope 3 emissions remained relatively stable, indicating that JCR Pharmaceuticals 's emissions have plateaued with no significant change in its value chain footprint.
What categories of Scope 3 emissions does JCR Pharmaceuticals disclose?
In 2022, JCR Pharmaceuticals reported emissions for 10 out of the 15 Scope 3 categories defined by the GHG Protocol.
This reflects a high level of granularity and transparency in the company's emissions reporting.
What are the main sources of JCR Pharmaceuticals's Scope 3 emissions?
In 2022, the largest contributors to JCR Pharmaceuticals's Scope 3 emissions were:
- Capital Goods (Cat. 2): 39,094 tCOâ‚‚e (49.2%)
- Purchased Goods and Services (Cat. 1): 38,635 tCOâ‚‚e (48.62%)
- Fuel- and Energy-Related Services (Cat. 3): 1,155 tCOâ‚‚e (1.45%)
JCR Pharmaceuticals's Scope 3 Emissions by Categories
Insights into JCR Pharmaceuticals's Total Carbon Footprint
In 2022, JCR Pharmaceuticals reported a total carbon footprint of 90,451 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 5.75% increase compared to 2021, suggesting a rise in emissions across its operations or value chain.
The largest contributor to JCR Pharmaceuticals's total carbon footprint was Scope 3 emissions, accounting for 87.86% of the company's total carbon footprint, followed by Scope 2 emissions at 8.48%.